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Mutations in mitochondrial (mt) DNA determine important human diseases. The majority
of the known pathogenic mutations are located in transfer RNA (tRNA) genes and are
responsible for a wide range of currently untreatable disorders. Experimental evidence
both in yeast and in human cells has shown that the detrimental effects of mt-tRNA point
mutations can be attenuated by increasing the expression of the cognate mt-aminoacyl-
tRNA synthetases (aaRSs). In addition, constitutive high levels of isoleucyl-tRNA
syntethase have been shown to reduce the penetrance of a homoplasmic mutation
in mt-tRNAIle in a small kindred. More recently, we showed that the isolated carboxy-
terminal domain of human mt-leucyl tRNA synthetase (LeuRS-Cterm) localizes to
mitochondria and ameliorates the energetic defect in transmitochondrial cybrids carrying
mutations either in the cognate mt-tRNALeu(UUR) or in the non-cognate mt-tRNAIle
gene. Since the mt-LeuRS-Cterm does not possess catalytic activity, its rescuing ability
is most likely mediated by a chaperon-like effect, consisting in the stabilization of the
tRNA structure altered by the mutation. All together, these observations open potential
therapeutic options for mt-tRNA mutations-associated diseases.
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Introduction
Mutations in genes coding for mt-tRNAs (MTTs) are responsible for a wide range of currently
untreatable pathologies. Clinical presentation may occur at any age, ranging from isolated organ-
speciﬁc disorders such as cardiomyopathy or hearing loss, to multisystem diseases including
myopathies, encephalopathies, deafness, diabetes and others (Yarham et al., 2010). Most mt-tRNA
pathogenic mutations are heteroplasmic (i.e., mutant and wild type molecules co-exist within the
same cell), and manifest clinically only when mutated mtDNA exceeds a threshold level, typically
60–90% (Greaves et al., 2012). However, homoplasmic pathogenic mutations (a condition where
all mtDNAmolecules are mutated in the cell) have been reported, either in association with tissue-
speciﬁc disorders (i.e., maternally inherited cardiomyopathy; Taylor et al., 2003; Perli et al., 2012)
or with devastating multisystem diseases (McFarland et al., 2002; Limongelli et al., 2004).
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Mitochondrial (mt) tRNA mutations would be expected to
cause impaired mt protein synthesis (i.e., defective transla-
tion of the 13 mtDNA-encoded protein subunits of the respi-
ratory chain), leading to a generalized OXPHOS defect. The
mechanism by which mutations induce a quantitative and/or
qualitative defect of mt translation is complex and not com-
pletely understood. Biochemical characterizations of mutant
tRNAs transcribed in vitro and studies on patients derived
transmitochondrial cybrids (herein cybrids) have shown that
mutations may negatively aﬀect diﬀerent steps of tRNA biogene-
sis and/or functioning, including processing, post-transcriptional
modiﬁcation, aminoacylation and translation (see for Review
Yarham et al., 2010; Suzuki et al., 2011). Most pathogenic muta-
tions directly aﬀect mt-tRNA tertiary structure and stability. This,
in turn, can hamper mt-tRNA interactions required for produc-
tive protein synthesis e.g., interactions with: (1) enzymes that
perform post-transcriptional modiﬁcations essential for transla-
tional accuracy and eﬃciency; (2) cognate aaRSs or other tRNA
synthetases, which may lead to non-charged or mischarged tRNA
formation; or (3) translation factors or ribosome, which would
aﬀect the rate or accuracy of translational initiation or elongation.
These alterations would be expected to cause generalized transla-
tion defects and, therefore, decreased levels of mtDNA-encoded
polypeptides. As mentioned above, mutations may also aﬀect
tRNA recognition by enzymes not directly involved in transla-
tion, e.g., enzymes that process mtDNA polycistronic transcripts,
thus leading to decreased steady-state levels of mature mt-tRNA
available for aminoacylation.
The most frequent and extensively studied mt-tRNA
mutation is m.3243A>G, one of the 32 disease-associated
mutations within the MTTL1 gene coding for mt-tRNALeu(UUR)
(http://www.mitomap.org/bin/view.pl/MITOMAP/MutationsRN
A). The eﬀects of this mutation are reported in Table 1.
An important issue that remains to be elucidated is the
remarkable heterogeneity of clinical phenotypes. the hetero-
plasmic m.3243A>G mutation has been reported to occur
in association with a number of clinical syndromes such as
encephalomyopathy, lactic acidosis and stroke-like episodes
(MELAS) syndrome; chronic progressive external ophthalmo-
plegia (CPEO); and maternally inherited diabetes and deafness
(MIDD). Both the speciﬁc energetic needs of aﬀected tissues
and, in case of heteroplasmic mutations, the variable ratios of
wild-type and mutant tRNAs in diﬀerent tissues, contribute to
generating phenotypic variability. However, other factors, such
as the eﬀect of environment, the mt genetic background, and
the interaction with nuclear genes involved in diﬀerent steps of
mt-tRNA processing andmodiﬁcation, may also aﬀect the pheno-
typic expression of the mutations. This is exempliﬁed by the case
of mt-tRNA homoplasmic mutations which show an extremely
variable clinical penetrance even within the same family, despite
in all individuals all mtDNA molecules are mutated.
The Penetrance of mt-tRNAs
Mutations can be Modulated by
Over-Expression of mt-aaRS
Proteins interacting with mt-tRNAs are able to eﬀectively rescue
the pathological phenotypes due to point mutations in mt-tRNA
genes. This has been ﬁrst demonstrated by the over-expression
of the nuclear gene coding for mt EF-Tu in yeast Saccharomyces
cerevisiae strains carrying point mutations in MTTL1 gene,
equivalent to those associated with human diseases (Feuermann
et al., 2003). EF-Tu is an evolutionarily conserved elongation
factor, which plays a central role in the translation process by
binding the aminoacylated tRNA, protecting it from hydrolysis,
and carrying it to the ribosome. The results obtained in the yeast
model have been paralleled in human cell lines. Overexpression
of mt elongation factors EF-Tu and EFG2 partially rescues the
severe respiratory chain deﬁciency of myoblasts carrying the
MELAS-associated m.3243A>G mutation in MTTL1 at homo-
plasmic levels (Sasarman et al., 2008). Subsequently, the detri-
mental eﬀects of mt-tRNA point mutations have been shown
to be modulated by the expression levels of additional genes, in
particular mt aaRSs. Studies on the yeast model revealed that
over-expression of the nuclear genes NAM2 and HTS1, coding
respectively for yeast mt-LeuRS and mt-HisRS (Natsoulis et al.,
1986; Zagorski et al., 1991) rescues the growth-defective pheno-
type of yeast strains carrying human equivalent point mutations
in the cognate mt-tRNAs (De Luca et al., 2006). Likewise, over-
expression of mt-LeuRS has been shown to correct the respiratory
chain deﬁciency of human patients-derived cybrids harboring the
m.3243A>G mutation in the MTTL1 gene. (Park et al., 2008; Li
and Guan, 2010).
TABLE 1 | Reported effects of m.3243A>G mutation on tRNALeu(UUR) structure, processing and function.
Effects of m.3243A>G mutation on tRNALeu(UUR) structure,
processing and function
References
Disruption of the L-shaped tertiary structure and decreased stability of the
mutant tRNA
Wittenhagen and Kelley (2002), Sohm et al. (2003)
Dimerization of mutated tRNAs Wittenhagen and Kelley (2002), Roy et al. (2005)
Reduced tRNALeu(UUR) steady-state levels Park et al. (2003)
Reduction of 3’-end processing efficiency Koga et al. (1993), Levinger et al. (2004)
Accumulation of processing intermediates (RNA19S) King et al. (1992)
Defect of uridine modification at the anticodon wobble position Yasukawa et al. (2000), Kirino et al. (2005)
Decreased aminoacylation level and efficiency Borner et al. (2000), Chomyn et al. (2000), Park et al. (2003), Sohm et al.
(2003).
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The ability to modulate the eﬀects of pathogenic mt-tRNA
mutations in human cells has been shown to be shared by other
mt-aaRSs belonging, like LeuRS, to Class I and subclass a. As
an example, the steady state levels of mutated mt-tRNAVal were
partially restored by over-expressing the cognate mt valyl-tRNA
synthetase (ValRS) in cybrid cell lines (Rorbach et al., 2008)
More recently, our group has shown that constitutively high lev-
els of mt-IleRS are associated with reduced penetrance of the
homoplasmic m.4277T>C mt-tRNAIle mutation, which causes
hypertrophic cardiomyopathy. Our in vivo ﬁndings were paral-
leled by results in mutant cybrids obtained by over-expression of
mt-IleRS (Perli et al., 2012).
Aminoacyl-tRNA synthetases are ubiquitously expressed
enzymes that catalyze the speciﬁc attachment of each of the
20 amino acids with cognate tRNAs bearing the correct anti-
codon triplet. Aminoacylation is a two-step reaction in which
amino acids are ﬁrst activated by ATP, forming an intermediate
aminoacyl-adenylate, and then transferred to the 3′-end of tRNA
to form the aminoacyl-tRNA end-product (Ibba and Soll, 2000).
Human cells contain aaRSs speciﬁc to cytoplasm, mitochondria
or, in some cases, both, depending on the cellular compartment
where they exert their catalytic activity and the set of tRNAs
used as substrates. Based on the architecture of their catalytic
binding domain, aaRSs are grouped in two classes, I and II
(Schimmel, 1987; Cusack et al., 1990; Eriani et al., 1990). Class
I aaRSs are speciﬁc for amino acids Val, Leu, Ile, Met, Cys, Glu,
Gln, Tyr, Trp, and Arg. Their active site is located in a Rossman
fold nucleotide-binding catalytic domain (made of six parallel β-
strands alternating to α-helices; Li et al., 1992). Class II aaRSs
are speciﬁc for amino acids Gly, Ala, Ser, Thr, Asn, Asp, Lys,
His, Phe, and Pro. They are mostly dimeric or multimeric, their
active site is contained in an anti-parallel β-sheet with ﬂanking
α-helices, and they share at least three conserved regions (Cusack
et al., 1991; Schimmel, 1991; Perona et al., 1993). Both class I and
class II aaRSs are further divided into a, b and c subclasses, each
comprising enzymes sharing sequence, structure and function
similarities. All aaRSs contain both a catalytic and an anticodon
recognition domain, which are required to catalyze the aminoa-
cylation reaction and recognize the tRNA molecule speciﬁc for
each cognate amino acid, respectively. To ensure translational
ﬁdelity, several aaRSs contain an additional editing domain able
to deacylate mischarged amino acids, with the aim of prevent-
ing insertion of incorrect amino acids during protein synthesis
(Beebe et al., 2008; Schimmel, 2008; Martinis and Boniecki, 2010;
Yao and Fox, 2013).
Although the main aaRSs function consists in charging tRNAs
with their cognate amino acids in the initiation step of pro-
tein synthesis, a number of additional functions have been
recently discovered to be carried out by these enzymes. During
evolution, cytoplasmic aaRSs have acquired additional non-
catalytic domains and insertions, dispensable for aminoacyla-
tion, which are involved in pathways of apoptosis, angiogenesis,
immune response, tumorigenesis and inﬂammation (Delarue
and Moras, 1993; Guo and Schimmel, 2013; Lo et al., 2014).
Initially, analogous domains with non-catalytic functions had
not been identiﬁed in mammalian mt aaRSs. However, domains
of both mt-TyrRS from Neurospora crassa and mt-LeuRS from
S. cerevisiae have been shown to be essential factors for the splic-
ing of several mt RNA group I introns (Akins and Lambowitz,
1987; Hsu et al., 2006). Deletion analysis showed that the splicing
function of yeast mt LeuRS resided in a sixty-amino acid region at
the carboxy-terminal end of the enzyme and that deletion of this
region had no impact on the aminoacylation activity (Li et al.,
1996). Interestingly, the homologous human mt-LeuRS-Cterm
conserves the splicing activity although there is no require-
ment for intron splicing following human mtDNA expression
(Houman et al., 2000).
The Carboxy-Terminal Domain of
mt-LeuRS is able to Rescue Defects
Associated with both Cognate and
Non-Cognate mt-tRNA Mutations in
Human Cells
An important feature of the yeast mt-LeuRS-Cterm, in view
of potential therapeutic developments, is the ability to rescue
defective phenotypes associated with human-equivalent point
mutations in yeast mt-tRNAs (Francisci et al., 2011). Recently,
we and others have shown that human mt-LeuRS-Cterm: (i) is
the region necessary and suﬃcient to ameliorate the mt defects of
patient-derived cybrids carrying mutations in both cognate and
non-cognate mt-tRNAs (namely, mt-tRNALeu(UUR) , mt-tRNAIle,
mt-tRNAVal, all of which are aminoacylated by Class Ia aaRSs);
and (ii) has a higher rescuing activity than the whole mt-LeuRS
toward all of the tested mutations (Hornig-Do et al., 2014; Perli
et al., 2014).
The demonstration that the catalytic function of mt-LeuRS-
Cterm is not required for its rescuing activity and the interactions
occurring between the LeuRS-Cterm domain and the cognate
tRNA in experimentally determined three-dimensional struc-
tures (see below) led us to speculate that the ability of this
domain to correct the biochemical phenotype associated with
pathogenic mt-tRNAmutations may be ascribed to a ‘chaperone-
like’ eﬀect. Both human (Perli et al., 2012) and yeast (Francisci
et al., 2005) mt-tRNAs bearing point mutations that determine
a defective phenotype have been previously shown to undergo
conformational and/or aminoacylation defects. We hypothe-
size that, by directly interacting with the mutated mt-tRNA,
the mt-LeuRS-Cterm stabilizes a native-like tRNA conformation
which would be, in turn, better equipped at establishing interac-
tions with proteins and other macromolecular partners required
for protein synthesis, and/or more resistant toward degradation
events.
Structural Basis of the Ability of
mt-LeuRS-Cterm to Interact with
Cognate and Non-Cognate mt-tRNAs
The hypothesis that the rescuing activity of human mt-LeuRS-
Cterm is mediated by a direct interaction with mutated
tRNA molecules is supported by the results of our in vitro
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surface plasmon resonance experiments. These demonstrated
that mt-LeuRS-Cterm is able to directly and speciﬁcally interact
with human cognate mt-tRNALeu(UUR) with high aﬃnity and sta-
bility, and with non-cognate mt-tRNAIle with 4-fold lower aﬃnity
(Perli et al., 2014).
Several 3D structures of LeuRS have been experimentally
determined by X-ray crystallography and are available from the
protein data bank (PDB; Berman et al., 2000). Although none
of these structures are from mitochondria, sequence analyses
reveals that both human and yeast mt LeuRS are closely related
to cytoplasmic LeuRS from the bacteria Thermus thermophilus
(Tukalo et al., 2005) and Escherichia coli (Palencia et al., 2012),
whose 3D structures have been determined in complex with the
cognate tRNALeu (Figure 1).
Analysis of the bacterial LeuRS structures (PDB IDs: 2BTE
and 4AS1) revealed that LeuRS-Cterm interacts with the ‘elbow
region’ of the cognate tRNA and establishes a higher num-
ber of contacts with the sugar-phosphate backbone than with
nucleotide-speciﬁc chemical groups (13 and 3, respectively, in
the higher resolution LeuRS-tRNALeu complex structure from
E. coli). The preferred interaction of human mt-LeuRS-Cterm
with ribose and phosphate oxygen atoms, which are present in
FIGURE 1 | Ribbon representation of the LeuRS-tRNALeu complex
from Thermus thermophilus determined by X-ray crystallography
(PDB ID: 2BTE) at a Resolution of 2.9 Å. The structural
domains of LeuRS are colored as follows: catalytic, yellow;
leucine-specific, pink; editing, cyan; anticodon-binding, lilac;
carboxy-terminal, green. The tRNA is colored orange and tRNA
bases are shown as sticks. Position A14, equivalent to m.3243A, is
highlighted by a red sphere.
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all tRNAs, may contribute to explain its ability to bind to both
cognate mt-tRNALeu(UUR) and non-cognate mt-tRNAIle, and res-
cue defects associated with point mutations in both tRNAs.
Additionally, analysis of the 3D models of human and yeast mt-
LeuRS-Cterm, built by homology using the 3D structure of E. coli
LeuRS as a template, showed that positive residues, which are
relatively distant in the amino acid sequences are spatially clus-
tered (Perli et al., 2014). This results in the formation of basic
patches on the domain surfaces, which might explain the ability
of both domains to be imported into mitochondria in spite of the
lack of a canonical MTS.
Future Perspectives
Currently, no reliable treatments or therapies are available for res-
piratory chain deﬁciencies due to mt-DNA encoded tRNA genes.
Strategies as diverse as those aimed at mt tRNA delivery or mt
ATP production increase have resulted in limited success.
Based on the evidences provided so far, the mt-LeuRS-
Cterm is both an attractive new candidate for future thera-
peutic applications in mt-tRNA related diseases by itself, and
opens a number of potential additional therapeutic avenues.
In this regard it is worthwhile to identify: (i) smaller mt-
LeuRS-Cterm fragments endowed with mt localization and
rescuing ability; (ii) further mutations in mt-tRNAs aminoa-
cylated by class I or II aaRS that can be rescued by
mt-LeuRS Cterm and/or smaller peptides thereof; and (iii)
additional aaRSs and/or peptides endowed with rescuing
ability.
It has been recently demonstrated in the yeast model
that the defective phenotype associated with human equiv-
alent point mutations in MTT genes can be rescued by
overexpressing short sequences (named β30_31 and β32_33,
∼15 amino acid long) derived from the human mt-LeuRS-
Cterm (Francisci et al., 2011). This suggests that mt-LeuRS-
Cterm-derived peptides may be used as therapeutic tools,
provided that suitable agents for mitochondria targeting are
developed to deliver them to their subcellular destination.
Such small mt-LeuRS-Cterm peptides may even prompt the
development of non-peptide organic molecules, especially if
the rescuing activity can be further restricted to smaller
regions.
Further studies on the yeast model have recently shown that
overexpressed mt-LeuRS-Cterm and β30_31 and β32_33 pep-
tides suppress the respiratory defects of the mutants in mt-tRNAs
aminoacylated by class II, as well as class I, mt-aaRS (Di Micco
et al., 2014).
Interestingly, the ability of the whole mt-LeuRS to rescue
pathological mutations in both cognate tRNALeu(UUR) and non-
cognate tRNAIle and mt-tRNAVal has been shown to be shared by
class Ia mt-IleRS and mt-ValRS in both human cells (Perli et al.,
2014) and the yeast model (Montanari et al., 2010). However,
at variance with mt-LeuRS-Cterm, the carboxy-terminal regions
from mt-IleRS and mt-ValRS exerted very limited rescuing activ-
ities in the yeast model (Di Micco et al., 2014). Indeed, the
absence of detectable sequence similarity between mt-LeuRS and
mt-IleRS or mt-ValRS human or yeast and the diﬀerent struc-
ture and tRNA binding mode detected in homologous enzymes
of known 3D structure indicate that the properties of mt-LeuRS-
Cterm are not necessarily shared by the carboxy-terminal domain
of diﬀerent aaRSs.
Finally, in view of potential therapeutic application, it is essen-
tial to further investigate the molecular mechanisms underlying
the activity of mt-LeuRS-Cterm and its derived peptides, by mea-
suring their eﬀect on multiple parameters of mt function. It is
expected that the recently reported availability of mouse models
of mt-tRNA mutation related disease (Shimizu et al., 2014) will
further boost research in this important medical ﬁeld.
Acknowledgments
This work was supported by Istituto Pasteur-Fondazione Cenci
Bolognetti, Telethon-Italy grant GGP13097 (to GdA) and
AFMTéléthon (to GdA). E.P. is a recipient of a Telethon
Foundation fellowship (grant GGP13097). We are grateful to
Patrizio Di Micco for providing his expertise for the three-
dimensional analysis of tRNA-Cterm interaction and to Laura
Frontali and Silvia Francisci for their very helpful discussions.
References
Akins, R. A., and Lambowitz, A. M. (1987). A protein required for splicing group
I introns in Neurospora mitochondria is mitochondrial tyrosyl-tRNA syn-
thetase or a derivative thereof. Cell 31, 331–345. doi: 10.1016/0092-8674(87)
90488-0
Beebe, K., Mock, M., Merriman, M., and Schimmel, P. (2008). Distinct domains
of tRNA synthetase recognize the same base pair. Nature 451, 90–93. doi:
10.1038/nature06454
Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H.,
et al. (2000). The protein data bank. Nucleic Acids Res. 28, 235–242. doi:
10.1093/nar/28.1.235
Borner, G. V., Zeviani, M., Tiranti, V., Carrara, F., Hoﬀmann, S., Gerbitz K. D.,
et al. (2000). Decreased aminoacylation of mutant tRNAs in MELAS but
not in MERRF patients. Hum. Mol. Genet. 9, 467–475. doi: 10.1093/hmg/
9.4.467
Chomyn, A., Enriquez, J. A., Micol, V., Fernandez-Silva, P., and Attardi, G. (2000).
The mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-
like episode syndrome-associated human mitochondrial tRNALeu(UUR)
mutation causes aminoacylation deﬁciency and concomitant reduced asso-
ciation of mRNA with ribosomes. J. Biol. Chem. 275, 19198–191209. doi:
10.1074/jbc.M908734199
Cusack, S., Berthet-Colominas, C., Härtlein, M., Nassar, N., and Leberman, R.
(1990). A second class of synthetase structure revealed by X-ray analysis of
Escherichia coli seryl-tRNA synthetase at 2.5 A. Nature 347, 249–255. doi:
10.1038/347249a0
Cusack, S., Hartlein, M., and Leberman, R. (1991). Sequence, structural and evo-
lutionary relationships between class 2 aminoacyl tRNA synthetases. Nucleic
Acids Res. 19, 3489–3498. doi: 10.1093/nar/19.13.3489
Delarue, M., and Moras, D. (1993). The aminoacyl-tRNA synthetase
family: modules at work. Bioessays 15, 675–687. doi: 10.1002/bies.
950151007
De Luca, C., Besagni, C., Frontali, L., Bolotin-Fukuhara, M., and Francisci,
S. (2006). Mutations in yeast mt-tRNAs: speciﬁc and general suppres-
sion by nuclear encoded tRNA interactors. Gene 377, 169–176. doi:
10.1016/j.gene.2006.04.003
DiMicco, P., Fazzi D’Orsi, M., Morea, V., Frontali, L., Francisci, S., and Montanari,
A. (2014). The yeast model suggests the use of short peptides derived from
Frontiers in Genetics | www.frontiersin.org 5 March 2015 | Volume 6 | Article 113
Giordano et al. LeuRS and mt-tRNA associated disease
mt LeuRS for the therapy of diseases due to mutations in several mt tRNAs.
Biochim. Biophys. Acta 1843, 3065–3074. doi: 10.1016/j.bbamcr
Eriani, G., Delarue, M., Poch, O., Gangloﬀ, J., and Moras, D. (1990). Partition of
tRNA synthetases into two classes based on mutually exclusive sets of sequence
motifs. Nature 347, 203–206. doi: 10.1038/347203a0
Feuermann, M., Francisci, S., Rinaldi, T., De Luca, C., Rohou, H., Frontali, L.,
et al. (2003). The yeast counterparts of human ‘MELAS’ mutations cause
mitochondrial dysfunction that can be rescued by overexpression of the mito-
chondrial translation factor EF-Tu. EMBO Rep. 4, 53–58. doi: 10.1038/sj.embor.
embor71.3
Francisci, S., De Luca, C., Oliva, R., Morea, V., Tramontano, A., and Frontali,
L. (2005). Aminoacylation and conformational properties of yeast mito-
chondrial tRNA mutants with respiratory deﬁciency. RNA 11, 914–927. doi:
10.1261/rna.2260305
Francisci, S., Montanari, A., De Luca, C., and Frontali, L. (2011). Peptides from
aminoacyl-tRNA synthetases can cure the defects due to mutations in mt tRNA
genes.Mitochondrion 11, 919–923. doi: 10.1016/j.mito.2011.08.006
Greaves, C. G., Reeve, A. K., Taylor, R. T., and Turnbull, D. M.
(2012). Mitochondrial DNA and disease. J. Pathol. 226, 274–286. doi:
10.1002/path.3028
Guo, M., and Schimmel, P. (2013). Essential nontranslational functions of tRNA
synthetases. Nat. Chem. Biol. 9, 145–153. doi: 10.1038/nchembio.1158
Hornig-Do, H. T., Montanari, A., Rozanska, A., Tuppen, H. A., Almalki, A. A.,
Abg-Kamaludin, D. P., et al. (2014). Human mitochondrial leucyl tRNA syn-
thetase can suppress non cognate pathogenic mt-tRNA mutations. The isolated
carboxy-terminal domain of human mitochondrial leucyl-tRNA synthetase res-
cues the pathological phenotype of mitochondrial tRNA mutations in human
cells. EMBO Mol. Med. 6, 183–193. doi: 10.1002/emmm.201303202
Houman, F., Rho, S. B., Zhang, J., Shen, X., Wang, C. C., Schimmeland, P.,
et al. (2000). A prokaryote and human tRNA synthetase provide an essential
RNA splicing function in yeast mitochondria. Proc. Natl. Acad. Sci. U.S.A. 97,
13743–13748. doi: 10.1073/pnas.240465597
Hsu, J., Rho, S. B., Vannella, K. M., and Martinis, S. A. (2006). Functional diver-
gence of a unique c-terminal domain od Leucyl-tRNA syntethase to accommo-
date its splicing and aminoacylation roles. J. Biol. Chem. 32, 23075–23082. doi:
10.1074/jbc.M601606200
Ibba, M., and Soll, D. (2000). Aminoacyl-tRNA synthesis. Annu. Rev. Biochem. 69,
617–650. doi: 10.1146/annurev.biochem.69.1.617
King, M. P., Koga, Y., Davidson, M., and Schon, E. A. (1992). Defects in mito-
chondrial protein synthesis and respiratory chain activity segregate with the
trnaleu(uur) mutation associated with mitochondrial myopathy, encephalopa-
thy, lactic acidosis, and strokelike episodes. Mol. Cell. Biol. 12, 480–490. doi:
10.1128/MCB.12.2.480
Kirino, Y., Goto, Y., Campos, Y., Arenas, J., and Suzuki, T. (2005). Speciﬁc cor-
relation between the wobble modiﬁcation deﬁciency in mutant tRNAs and the
clinical features of a human mitochondrial disease. Proc. Natl. Acad. Sci. U.S.A.
102, 7127–7132. doi: 10.1073/pnas.0500563102
Koga, Y., Davidson, M., Schon, E. A., and King, M. P. (1993). Fine map-
ping of mitochondrial RNAs derived from the mtDNA region containing a
point mutation associated with MELAS. Nucleic Acids Res. 21, 657–662. doi:
10.1093/nar/21.3.657
Levinger, L., Oestreich, I., Florentz, C., and Morl, M. (2004). A pathogenesis-
associated mutation in human mitochondrial tRNALeu(UUR) leads to reduced
3’-end processing and CCA addition. J. Mol. Biol. 337, 535–544. doi:
10.1016/j.jmb.2004.02.008
Li, G. Y., Becam, A. M., Slonimski, P. P., and Herbert, C. J. (1996). In vitro mutage-
nesis of the mitochondrial leucyl tRNA synthetase of Saccharomyces cerevisiae
shows that the suppressor activity of the mutant proteins is related to the
splicing function of the wild-type protein.Mol. Gen. Genet. 252, 667–675.
Li, G. Y., Herbert, C. J., Labouesse, M., and Slonimski, P. P. (1992). In vitro
mutagenesis of the mitochondrial leucyl-tRNA synthetase of S. cerevisiae
reveals residues critical for its in vivo activities. Curr. Genet. 22, 69–74. doi:
10.1007/BF00351744
Li, R., and Guan, M. X. (2010). Human mitochondrial leucyl-tRNA synthetase
corrects mitochondrial dysfunctions due to the tRNALeu(UUR) A3243G
mutation, associated with mitochondrial encephalomyopathy, lactic acidosis,
and stroke-like symptoms and diabetes. Mol. Cell. Biol. 30, 2147–2154. doi:
10.1128/MCB.01614–1619
Limongelli, A., Schaefer, J., Jackson, S., Invernizzi, F., Kirino, Y., Suzuki, T., et al.
(2004). Variable penetrance of a familial progressive necrotising encephalopa-
thy due to a novel tRNA(Ile) homoplasmic mutation in the mitochondrial
genome. J. Med. Genet. 41, 3492–3499. doi: 10.1136/jmg.2003.016048
Lo, W. S., Gardiner, E., Xu, Z., Lau, C. F., Wang, F., Zhou, J. J., et al. (2014). Human
tRNA synthetase catalytic nulls with diverse functions. Science 345, 328–332.
doi: 10.1126/science.1252943
Martinis, S. A., and Boniecki, M. T. (2010). The balance between pre-and
post-transfer editing in tRNA synthetases. FEBS Lett. 584, 455–459. doi:
10.1016/j.febslet.2009.11.071
McFarland, R., Clark, K. M., Morris, A. A., Taylor, R. W., Macphail, S.,
Lightowlers, R. N., et al. (2002). Multiple neonatal deaths due to a homo-
plasmic mitochondrial DNA mutation. Nat. Genet. 30,145–146. doi: 10.1038/
ng819
Montanari, A., De Luca, C., Frontali, L., and Francisci, S. (2010). Aminoacyl-tRNA
synthetases are multivalent suppressors of defects due to human equivalent
mutations in yeast mt tRNA genes. Biochim. Biophys. Acta 1803, 1050–1057.
doi: 10.1016/j.bbamcr.2010.05.003
Natsoulis, G., Hilger, F., and Fink, G. R. (1986). The HTS1 gene encodes both
the cytoplasmic and mitochondrial histidine-tRNA syntethase of S. Cell 46,
235–243. doi: 10.1016/0092-8674(86)90740-3
Palencia, A., Crépin, T., Vu, M. T., Lincecum, T. L. Jr., Martinis, S. A., and Cusack,
S. (2012). Structural dynamics of the aminoacylation and proofreading func-
tional cycle of bacterial leucyl-tRNA synthetase. Nat. Struct. Mol. Biol. 19,
677–684. doi: 10.1038/nsmb.2317
Park, H., Davidson, E., and King, M. P. (2003). The pathogenic A3243G mutation
in human mitochondrial tRNALeu(UUR) decreases the eﬃciency of aminoacy-
lation. Biochemistry 42, 958–964. doi: 10.1021/bi026882r
Park, H., Davison, E., and King, M. (2008). Overexpressed mitochondrial
leucyl-tRNA synthetase suppresses the A3243G mutation in the mito-
chondrial tRNALeu(UUR) gene. RNA 14, 2407–2416. doi: 10.1261/rna.12
08808
Perli, E., Giordano, C., Pisano, A., Montanari, A., Campese, A. F., Reyes, A.,
et al. (2014). The isolated carboxy-terminal domain of human mitochon-
drial leucyl-tRNA synthetase rescues the pathological phenotype of mito-
chondrial tRNA mutations in human cells. EMBO Mol. Med. 6,169–82. doi:
10.1002/emmm.201303198
Perli, E., Giordano, C., Tuppen, H. A., Montopoli, M., Montanari, A., Orlandi,
M., et al. (2012). Isoleucyl-tRNA synthetase levels modulate the pene-
trance of a homoplasmic m.4277T>C mitochondrial tRNAIle mutation
causing hypertrophic cardiomyopathy. Hum. Mol. Genet. 21, 85–100. doi:
10.1093/hmg/ddr440
Perona, J. J., Rould,M. A., and Steitz, T. A. (1993). Structural basis for transfer RNA
aminoacylation by Escherichia coli glutaminyl-tRNA synthetase. Biochemistry
32, 8758–8771. doi: 10.1021/bi00085a006
Rorbach, J., Yusoﬀ, A. A., Tuppen, H., Abg-Kamaludin, D. P., Chrzanowska-
Lightowlers, Z. M., Taylor, R. W., et al. (2008). Overexpression of human
mitochondrial valyl tRNA synthetase can partially restore levels of cognate
mt-tRNAVal carrying the pathogenic C25U mutation. Nucleic Acids Res. 36,
3065–3074. doi: 10.1093/nar/gkn147
Roy, M. D., Wittenhagen, L. M., and Kelley, S. O. (2005). Structural prob-
ing of a pathogenic tRNA dimer. RNA 11, 254–260. doi: 11:254–260.
10.1261/rna.7143305
Sasarman, F., Antonicka, H., and Shoubridge, E. A. (2008). TheA3243G
tRNALeu(UUR) MELAS mutation causes amino acid misincorporation and
a combined respiratory chain assembly defect partially suppressed by over-
expression of EFTu and EFG2. Hum. Mol. Genet. 17, 3697–3707. doi:
10.1093/hmg/ddn265
Schimmel, P. (1987). Aminoacyl tRNA synthetases: general scheme of structure-
function relationships in the polypeptides and recognition of transfer RNAs.
Annu. Rev. Biochem. 56, 125–158. doi: 10.1146/annurev.bi.56.070187.001013
Schimmel, P. (1991). Classes of aminoacyl-tRNA synthetases and the establish-
ment of the genetic code. Trends Biochem. Sci. 16, 1–3. doi: 10.1016/0968-
0004(91)90002-D
Schimmel, P. (2008). Development of tRNA synthetases and connection to genetic
code and disease. Protein Sci. 17, 1643–1652. doi: 10.1110/ps.037242.108
Shimizu, A., Mito, T., Hayashi, C., Ogasawara, E., Koba, R., Negishi, I., et al.
(2014). Transmitochondrial mice as models for primary prevention of diseases
Frontiers in Genetics | www.frontiersin.org 6 March 2015 | Volume 6 | Article 113
Giordano et al. LeuRS and mt-tRNA associated disease
caused by mutation in the tRNA(Lys) gene. Proc. Natl. Acad. Sci. U.S.A. 111,
3104–3109. doi: 10.1073/pnas.1318109111
Sohm, B., Frugier, M., Brulé, H., Olszak, K., Przykorska, A., and Florentz, C. M. D.
(2003). Towards understanding human mitochondrial leucine aminoacy-
lation identity. J. Mol. Biol. 328, 995–1010. doi: 10.1016/S0022-2836(03)
00373-5
Suzuki, T., Nagao, A., and Suzuki, T. (2011). Humanmitochondrial tRNAs: biogen-
esis, function, structural aspects, and disease. Annu. Rev. Genet. 45, 299–329.
doi: 10.1146/annurev-genet-110410-132531
Taylor, R. W., Giordano, C., Davidson, M. M., d’ Amati, G., Bain, H., Hayes, C. M.,
et al. (2003). A homoplasmic mitochondrial transfer ribonucleic acid mutation
as a cause of maternally inherited hypertrophic cardiomyopathy. J. Am. Coll.
Cardiol. 41, 1786–1796. doi: 10.1016/S0735-1097(03)00300-0
Tukalo, M., Yaremchuk, A., Fukunaga, R., Yokoyama, S., and Cusack, S. (2005).
The crystal structure of leucyl-tRNA synthetase complexed with tRNALeu in
the post-transfer-editing conformation. Nat. Struct. Mol. Biol. 12, 923–930. doi:
10.1038/nsmb986
Wittenhagen, L. M., and Kelley, S. O. (2002). Dimerization of a pathogenic
human mitochondrial tRNA. Nat. Struct. Biol. 9, 586–590. doi: 10.1038/
nsb820
Yao, P., and Fox, P. L. (2013). Aminoacyl-tRNA synthetases in medicine and
disease. EMBO Mol. Med. 5, 332–343. doi: 10.1002/emmm.201100626
Yarham, J. W., Elson, J. L., Blakely, E. L., McFarland, R., and Taylor, R. W.
(2010). Mitochondrial tRNA mutations and disease. RNA 1, 304–324. doi:
10.1002/wrna.27
Yasukawa, T., Suzuki, T., Ueda, T., Ohta, S., andWatanabe, K. (2000).Modiﬁcation
defect at anticodon wobble nucleotide of mitochondrial tRNAsLeu(UUR)
with pathogenic mutations of mitochondrial myopathy, encephalopathy, lac-
tic acidosis, and stroke-like episodes. J. Biol. Chem. 275, 4251–4257. doi:
10.1074/jbc.275.6.4251
Zagorski,W., Castaing, B., Herbert, C. J., Labouesse,M., Martin, R., and Slonimski,
P. P. (1991). Puriﬁcation and characterization of the Saccharomyces cerevisiae
mitochondrial leucyl-tRNA synthetase. J. Biol. Chem. 266, 2537–2541.
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or ﬁnancial relationships that could be
construed as a potential conﬂict of interest.
Copyright © 2015 Giordano, Morea, Perli and d’Amati. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Genetics | www.frontiersin.org 7 March 2015 | Volume 6 | Article 113
